Jointown Pharmaceuticals Group Co Ltd (600998) Report Interpretation

Overview

This H126 review assesses Jointown's operating performance, cash-collection progress and growth outlook amid healthcare-distribution policy and regulatory headwinds. UBS sees revenue momentum and channel expansion as intact, retains Buy, and lowers its target price after modest forecast revisions.

Core views

Jointown reported H126 revenue of Rmb87.3bn, up 7.6% YoY, which UBS viewed as in line with expectations. Net profit attributable to shareholders fell 17.0% YoY to Rmb1.20bn, while recurring net profit attributable to shareholders rose 3.2% to Rmb0.98bn and was slightly below market expectations in UBS's view. The institution attributes the topline expansion principally to distribution to hospitals and online B2B sales, while a higher selling-expense ratio from investment in new businesses modestly weighed on net margin. Hospital distribution remained resilient despite policy and regulatory pressures. Revenue from distribution to public hospitals rose about 10% in H126; management attributed this to Jointown's increasing market share and its greater exposure to volume-based procurement products, where demand is more rigid. UBS also highlights the company's positioning in primary medical institutions and ex-hospital channels, differentiating it from other leading pharmaceutical distributors. New-retail channels provided a second growth engine. Distribution revenue to leading e-commerce platforms, including JD Health and Meituan, increased 28.8% YoY to Rmb5.6bn. Revenue at Yao Jiu Jiu, Jointown's digital B2B distribution platform, grew 18.9% YoY to Rmb7.5bn. Hao Yao Shi, the pharmacy-franchising brand, reached 36,120 stores at end-June, up from more than 34,500 at end-2025, while distribution revenue to franchised stores rose 23.2% YoY to Rmb4.2bn. Cash conversion improved modestly. Operating cash outflow narrowed to Rmb2.78bn from Rmb2.82bn in H125, mainly because receivables collection improved. Management stated that total accounts-receivable days declined by seven days YoY to 67 in Q226, while hospital receivable days decreased by two days to 173. UBS treats this progress as a supportive operating development but does not indicate that working-capital pressure has been eliminated. UBS left its broad operating outlook largely unchanged and expects high-single-digit revenue growth in 2026, ahead of pharmaceutical-distribution industry growth. Its reasoning rests on Jointown's alignment with accelerating prescription-drug sales outside public hospitals, rising online penetration in pharmaceutical retail, and policy support for primary-level medical institutions. Following the results, UBS adjusted its 2026-28E EPS estimates by -4% to +3%. It reduced the price target to Rmb6.10 from Rmb6.70 while keeping its WACC assumption unchanged at 8.8%; the new DCF-based target implies 15x 2026E P/E. UBS maintained a 12-month Buy rating. The report shows forecast price appreciation of 24.0%, a 3.8% forecast dividend yield, and a 27.8% forecast stock return versus a 6.8% market-return assumption.

Analysis framework

UBS compares H126 revenue and profit with expectations, then examines the contribution of hospital distribution, online B2B, pharmacy franchising and receivables collection. It carries these operating findings into its revenue-growth outlook, revises 2026-28E EPS estimates, and derives the target price using discounted cash flow analysis.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  UBS values Jointown by discounting projected cash flows using an unchanged 8.8% WACC, producing a Rmb6.10 price target.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Pharmaceutical-distribution channel analysis

  The report assesses growth through hospital distribution, online platforms, digital B2B distribution and franchised pharmacies to explain revenue momentum and competitive positioning.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Jointown Pharmaceuticals Group Co Ltd (600998.SH)

  Primary covered company; UBS maintains Buy based on growth in distribution and new-retail channels.

  Strengths

  Rising hospital-distribution market share, exposure to volume-based procurement products, and growth in online B2B and pharmacy-franchise channels.

  Weaknesses

  Higher selling-expense ratio from investment in new businesses slightly weighed on net margin.

  Comparison

  UBS describes Jointown as the largest non-SOE pharmaceutical distributor in China, with advantages in primary medical institutions and ex-hospital channels relative to the other three leading distributors.

  Risks

  Margin erosion from GPOs, delays in REIT issuance, and stronger competition in ex-hospital distribution.

Key data

• H126 revenueRmb87.3bn+7.6% YoY; in line with expectations in UBS's view.
• H126 net profit attributable to shareholdersRmb1.20bn-17.0% YoY.
• H126 recurring net profit attributable to shareholdersRmb0.98bn+3.2% YoY; slightly below market expectations in UBS's view.
• E-commerce-platform distribution revenueRmb5.6bn+28.8% YoY.
• Yao Jiu Jiu revenueRmb7.5bn+18.9% YoY.
• Hao Yao Shi store count36,120At end-June, versus more than 34,500 at end-2025.
• Total accounts-receivable days67 daysDown seven days YoY in Q226.
• 2026-28E EPS revisions-4% to +3%Fine-tuned after the results.

Impact & implications

UBS argues that Jointown's hospital-distribution resilience, expanding ex-hospital and online channels, and modestly improved receivables collection support growth above the distribution-industry pace. However, investment in new businesses has increased selling costs and pressured margins, contributing to the lower target price despite the maintained Buy rating.

Risks

• Larger-than-expected margin erosion from GPOs could pressure profitability.
• Delays in REIT issuance are a stated company risk.
• Intensifying competition in the ex-hospital distribution market could affect growth and margins.
• Medical-product price cuts linked to medical-insurance cost control could hurt distributor revenue and margins.
• Ongoing anti-corruption campaigns are a sector risk.

What to watch

• Growth in public-hospital distribution amid policy and regulatory headwinds.
• Momentum in e-commerce-platform distribution, Yao Jiu Jiu and Hao Yao Shi franchised-store distribution.
• Further changes in receivables days and operating cash flow.
• Selling-expense trends and the effect of new-business investment on margins.
• Progress of REIT issuance and competitive conditions in ex-hospital distribution.